PTOISBIGE (05-07)
Approved for use through 09/30/2007 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are requir

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		10824856		
	Filing Date		2004-04-14		
	First Named Inventor Patri		k Dooling Bossman		
	Art Unit		2162		
	Examiner Name	Thu-N	lguyet Le		
	Attorney Docket Number		SVL920030141US1		

		· ·			U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date   Name of Patentee or Applicant   Re		Releva	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1										
If you wis	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	reation Name of Patentee or Applicant Re		Releva		Lines where ges or Relev		
	1	20060149695	A1	2006-07	-06	Bossman et al.					
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	GN PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup> Publication Date Name of Patentee or Applicant of cited Document		or v	vhere Rel	or Relevant	т.	
	1										С
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	I lease click the Add	button	Add		_
			NON	1-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.						Τs					

#### 

1	Office Action mailed 05/04/2007 for patent application no. 19/752,915, titled "Method, system, and program for statistics management", final rejection <11 pages>	
2	Office Action mailed 87/01/2006 for patient application no. 10/752,915, titled "Method, system, and program for statistics management", non-final rejection <8 pages>	
3		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Plated Documents at Invest (ISPTO, GOL) or IMPER 961.64. 2 Enter office that issued the document, by the Involved ow (IMPO Standard ST.3). 3 "For Implanees plant for counters, the orlication of the year of the register or Implant protect the serial runnivers of the plant document.

\*\*Your of Gournet by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark here if English inappages streations in statistact.\*\*

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10824856	
	Filing Date		2004-04-14	
First Named Inventor Patric		Patric	k Dooling Bossman	
	Art Unit		2162	
Examiner Name Thu-N		Thu-N	lguyet Le	
Attorney Docket Number		er	SVL920030141US1	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(4)(2)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Janet M. Skafar/	Date (YYYY-MM-DD)	2007-06-15
Name/Print	Janet M. Skafar	Registration Number	41315

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.